Public Health Agency of Canada researchers have shown that a cocktail of three antibodies, dubbed ZMab, improved the survival of nonhuman primates infected by Ebola virus. ZMab is licensed to Defyrus, which plans to establish commercial-scale manufacture of the therapy and carry out biodistribution and toxicology studies.